Loss of bcl-2 expression in ductal carcinoma in situ of the breast relates to poor histological differentiation and to expression of p53 and c- erbB-2 proteins

Histopathology

Volumn 33, Issue 6, 1998, Pages 531-536

  Quinn, C M ^a   Ostrowski, J L ^a   Harkins, L ^a   Rice, A J ^a   Loney, D P ^a  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

Author keywords

Bcl 2; C erbB 2; Ductal carcinoma in situ; Histological differentiation; Oestrogen receptor; P53

Indexed keywords

ESTROGEN RECEPTOR; ONCOPROTEIN; PROTEIN BCL 2; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER GRADING; CARCINOMA IN SITU; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; INVASIVE CARCINOMA; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR DIFFERENTIATION;

EID: 0031672142     PISSN: 03090167     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2559.1998.00505.x     Document Type: Article

References (38)

1. Tsujimoto Y, Cossman J, Jaffe E, Croce C. Involvement of the bcl-2 gene in human follicular lymphoma. Science 1985; 228; 1440-1443.
2. Hockenbery DM, Zutter M, Hickey W, Nahm M, Korsmeyer SJ. Bcl-2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc. Natl. Acad. Sci. 1991; 88; 6961-6965.
3. Nathan B, Anbazhagan R, Dyer M, Ebbs SR, Jayatilake H, Gusterson BA. Expression of bcl-2-like immunoreactivity in the normal breast and in breast cancer. The Breast 1993; 2; 134-137.
4. Doglioni C, Dei Tos AP, Laurino L, Chiarelli C, Barbareschi M, Viale G. The prevalence of bcl-2 immunoreactivity in breast carcinomas and its clinicopathological correlates, with particular reference to oestrogen receptor status. Virchows Arch. 1994; 424; 47-51.
5. Gee JM, Robertson JF, Ellis IO et al. Immunocytochemical localization of bcl-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. Int. J. Cancer 1994; 59; 619-628.
6. Silvestrini R, Veneroni S, Daidone MG et al. The bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. JNCI 1994; 86; 499-504.
7. Lipponen P, Pietilainen T, Kosma VM, Aaltomaa S, Eskelinen M, Syrjanen K. Apoptosis suppressing protein bcl-2 is expressed in well-differentiated breast carcinomas with favourable prognosis. J. Pathol. 1995; 177; 49-55.
8. Lane DP. p53, guardian of the genome. Nature 1992; 358; 15-16.
9. Levine AL, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 1991; 351; 453-456.
10. Hollstein M, Sidransky D, Vogelstein B, Harris C. p53 mutations in human cancers. Science 1991; 253; 49-53.
11. Haldar S, Negrini M, Monne M, Sabbioni S, Croce CM. Down-regulation of bcl-2 by p53 in breast cancer cells. Cancer Res. 1994; 54; 2095-2097.
12. Kaklamanis L, Savage A, Mortensen N et al. Early expression of bcl-2 protein in the adenoma-carcinoma sequence of colorectal neoplasia. J. Pathol. 1996; 179; 10-14.
13. Shiina H, Igawa M, Urakami S, Honda S, Shirakawa H, Ishibe T. Immunohistochemical analysis of bcl-2 expression in transitional cell carcinoma of the bladder. J. Clin. Pathol. 1996; 49; 395-399.
14. Holland R, Peterse JL, Millis RR et al. Ductal carcinoma in situ: A proposal for a new classification. Semin. Diagn. Pathol. 1994; 11; 167-180.
15. Quinn CM, Ostrowski JL, Parkin GJS, Horgan K, Benson EA. Ductal carcinoma in situ of the breast: the clinical significance of histological classification. Histopathology 1997; 30; 113-119.
16. Nathan B, Anbazhagan R, Clarkson P, Bartkova J, Gusterson B. Expression of bcl-2 in the developing human fetal and infant breast. Histopathology 1994; 24; 73-76.
17. Reed JC. Bcl-2 and the regulation of programmed cell death. J. Cell Biol. 1994; 124; 1-6.
18. Vaux D, Cory S, Adams JM. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalise pre-B cells. Nature 1988; 335; 440-442.
19. Siziopikou KP, Prioleau JE, Harris JR, Schnitt SJ. Bcl-2 expression in the spectrum of preinvasive breast lesions. Cancer 1996; 77; 499-506.
20. Kapucuoglu N, Losi L, Eusebi V. Immunohistochemical localization of bcl-2 and bax proteins in in situ and invasive duct breast carcinomas. Virchows Arch. 1997; 430: 17-22.
21. Mustonen M, Raunio H, Paakko P, Soini Y. The extent of apoptosis is inversely associated with bcl-2 expression in premalignant and malignant breast lesions. Histopathology 1997; 31; 347-354.
22. Mack L, Kerkvleit N, Doig G, O'Malley FP. Relationship of a new histological categorisation of ductal carcinoma in situ of the breast with size and the immunohistochemical expression of p53, c-erbB2, bcl-2, and Ki-67. Hum. Pathol. 1997; 28; 974-979.
23. Silvestrini R, Benini E, Veneroni S et al. p53 and bcl-2 expression correlates with clinical outcome in a series of node-positive breast cancer patients. J. Clin. Oncol. 1996; 14; 1604-1610.
24. Pezzella F, Gatter K. What is the value of bcl-2 protein detection for histopathologists? Histopathology 1995; 26; 89-93.
25. Kernohan NM, Cox LS. Regulation of apoptosis by bcl-2 and its related proteins: immunochemical challenges and therapeutic implications. J. Pathol. 1996; 179; 1-3.
26. Miyashita T, Krajewski S, Krajewska M et al. Tumour suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 1994; 9; 1799-1805.
27. van de Vijver MJ, Peterse JL, Mooi WJ et al. Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N. Engl. J. Med. 1988; 319; 1239-1245.
28. Bartkova J, Barnes DM, Millis RR, Gullick WJ. Immunohistochemical demonstration of c-erbB2 protein in mammary ductal carcinoma in situ. Hum. Pathol. 1990; 21; 1164-1167.
29. Ramachandra S, Machin L, Ashley S, Monaghan P, Gusterson BA. Immunohistochemical distribution of c-erbB2 in in situ breast carcinoma - a detailed morphological analysis. J. Pathol. 1990; 161; 7-14.
30. Poller DN, Roberts EC, Bell JA, Elston CW, Blamey RW, Ellis IO. p53 protein expression in mammary ductal carcinoma in situ: relationship to immunohistochemical expression of estrogen receptor and c-erbB2 protein. Hum. Pathol. 1993; 24; 463-468.
31. Bobrow LG, Happerfield LC, Gregory WM, Springall RD, Millis RR. The classification of ductal carcinoma in situ and its association with biological markers. Sem. Diagn. Pathol. 1994; 11; 199-207.
32. Leal CB, Schmitt FC, Bento MJ, Maia NC, Lopes CS. Ductal carcinoma in situ of the breast. Histologic categorization and its relationship to ploidy and immunohistochemical expression of hormone receptors, p53, and c-erbB-2 protein. Cancer 1995; 75; 2123-2131.
33. Johnston SR, MacLennan KA, Sacks NP, Salter J, Smith IE, Dowsett M. Modulation of bcl-2 and Ki-67 expression in oestrogen receptor-positive human breast cancer by tamoxifen. Eur J. Cancer 1995; 30A; 1663-1669.
34. Leek RD, Kaklamanis L, Pezzella F, Gatter KC, Harris AL. Bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer. Br. J. Cancer 1994; 69; 135-139.
35. Hellemans P, van Dam PA, Weyler J, van Oosterom AT, Buytaert P, Van Marck E. Prognostic value of bcl-2 expression in invasive breast cancer. Br. J. Cancer 1995; 72; 354-360.
36. van Slooten H-J, Clahsen PC, van Dierendonck JH et al. Expression of bcl-2 in node-negative breast cancer is associated with various prognostic factors, but does not predict response to one course of perioperative chemotherapy. Br. J. Cancer 1996; 74; 78-85.
37. Miyashita T, Reed JC. Bcl-2 oncoprotein blocks chemotherapy induced apoptosis in a human leukaemia cell line. Blood 1993; 81; 151-157.
38. Epperly MW, Santucci MA, Reed JC, Shields D, Halloran A, Greenberger JS. Expression of the human bcl-2 transgene increases the radiation resistance of a haemopoeitic progenitor cell line. Radiat. Oncol. Invest. 1994; 2; 77-83.